See enclosed PDF.
Recommended Reading
-
2025/26Interim financial results, H1 2025/261 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth1 in constant currencies. Strong quarter in Chronic Care and...
Read More -
The contract is awarded for products that bring improvement to the healthcare industry. Coloplast, a global medical device company and market leader in intimate healthcare, has received an Innovative...
Read More